Roivant Sciences Ltd.

NasdaqGS ROIV

Roivant Sciences Ltd. Net Income for the year ending March 31, 2024: USD 4.35 B

Roivant Sciences Ltd. Net Income is USD 4.35 B for the year ending March 31, 2024, a 0.00% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Roivant Sciences Ltd. Net Income for the year ending March 31, 2024 was USD 4.35 B, a 531.00% change year over year.
Roivant Sciences Ltd. Net Income for the year ending March 31, 2023 was USD -1.01 B, a -19.37% change year over year.
Roivant Sciences Ltd. Net Income for the year ending March 31, 2022 was USD -845.26 M, a -4.45% change year over year.
Roivant Sciences Ltd. Net Income for the year ending March 31, 2021 was USD -809.23 M, a -167.41% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqGS: ROIV

Roivant Sciences Ltd.

CEO	Mr. Matthew Gline
IPO Date	Dec. 8, 2020
Location	United Kingdom
Headquarters	11-12 St. James's Square
Employees	908
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Key trends

Past 5 years